Latest filing published 13 Feb 2026 for Pacira BioSciences, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by Brendan Teehan span 2 companies, the busiest being Acadia Pharmaceuticals Inc and Pacira BioSciences, Inc. In total, 31 filings cover trades dated from 6 January 2022 to 11 February 2026.
The open-market record consists of 8 sales worth €494k, with no purchase. Besides market trades, the filings include 7 share grants and 16 option exercises.
On 13 February 2026 came the latest disclosure, a share grant in Pacira BioSciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 31 declarations